OCTAPHARMA


Associated tags: Octapharma, Critical care, Immunotherapy, Patient, Plasma, Pharmaceutical industry, Vaccine, Research, Haemophilia, Disease, Factor VIII, Congress, Safety, VIII, Bleeding

Locations: SCHWEIZ, SWITZERLAND

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Ge

Retrieved on: 
Wednesday, January 17, 2024
Factor VIII, Senior, Octapharma, Patient, Research, Nosebleed, SLAM, VWD, Trial of the century, Pharmaceutical industry

The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.

Key Points: 
  • The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
  • The results provide compelling evidence for the use of regular prophylaxis in people with VWD.
  • "The new data from the WIL-31 study provide strong evidence for the use of wilate® prophylaxis in people with all types of VWD.
  • In such instances, indirect treatment comparisons can be used to compare the effects of different treatments.

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, January 3, 2024
Phase, Coagulation, Food, Emergency medicine, Risk, Vitamin K, PCC, Hemostasis, FDA, Warfarin, Bleeding, INR, Massachusetts General Hospital, Hospital, Thrombophilia, MD, Doctor of Philosophy, Factor X, Factor IX, Clinical trial, Prothrombin time, Trial of the century, Coagulation factor VII, Octapharma, VKA, Patient, Safety, Harvard Medical School, Thrombin, Pharmaceutical industry

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

Key Points: 
  • The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
  • Octapharma has the Balfaxar® production flexibility to ensure consistent supply for hospitals and medical providers.
  • "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future.
  • Balfaxar® met the primary endpoint of hemostatic efficacy in patients on a vitamin K antagonist undergoing urgent surgery with significant bleeding risk.

Octapharma USA: FDA Grants Expanded Approval to wilate® as the First VWF Concentrate for Prophylaxis in All Types of VWD

Retrieved on: 
Tuesday, December 5, 2023
Woman, Research, Safety, Food, Ageing, Disease, Hematology, Patient, Prevalence, FDA, ABR, Caregiver, MD, Bleeding, VWF, Bes, Haemophilia, Coagulopathy, Quality of life, Shriners Hospitals for Children, Observational study, Therapy, Health, VWD, Pharmaceutical industry, Nursing, Birth control

PARAMUS, N.J., Dec. 5, 2023 /PRNewswire/ -- Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label now includes routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD), the most prevalent bleeding disorder in the United States. Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.

Key Points: 
  • Wilate® is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of VWD, marking a significant milestone in the field.
  • "The approval of wilate® for VWD prophylaxis is a welcome new treatment option that can be life-saving for many patients.
  • Increased use of VWF prophylaxis in VWD patients may lead to improved patient care and a reduced burden of disease."
  • In tandem with this approval, Octapharma USA extends its commitment to patient care through the Factor My Way patient support program.

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Retrieved on: 
Tuesday, October 31, 2023
Haemophilia, Factor VIII, European Journal, PROPEL, PROTECT, Exercise, Georgetown University Medical Center, VIII, Georgetown Lombardi Comprehensive Cancer Center, Efmoroctocog alfa, Patient, Pharmaceutical industry, Dentistry

The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.

Key Points: 
  • The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
    Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis.
  • The results can be considered by clinicians and patients when treatment decisions are being made."
  • MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3.
  • In addition, a short video summarising the results is available in the online version of the article.

Octapharma USA Presents Factor Concentrates for Perioperative Bleeding Symposium for ASA Annual Meeting Attendees

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, Thrombophilia, Algorithm, American Society of Anesthesiologists, Disease, Food, VKA, Bleeding, PST, MD, Society, Mortality, Factor, Hospital, FDA, Food and Drug Administration, Warfarin, Toronto General Hospital, PCC, FC, Octapharma, Duke University, Hemostasis, The Reconstruction (1970 film), ASA, Moscone Center, Toronto, Patient, Nightclub, Dentistry, Pharmaceutical industry, Fibrinogen, Research

PARAMUS, N.J., Oct. 10, 2023 /PRNewswire/ -- Octapharma USA will sponsor the scientific symposium, Factor Concentrates for Perioperative Bleeding – Global Perspectives, Sunday, October 15th in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco.

Key Points: 
  • PARAMUS, N.J., Oct. 10, 2023 /PRNewswire/ -- Octapharma USA will sponsor the scientific symposium, Factor Concentrates for Perioperative Bleeding – Global Perspectives, Sunday, October 15th in conjunction with the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco.
  • The symposium will address current gaps in research related to factor concentrates, including prothrombin complex concentrates (PCC) and fibrinogen concentrates (FC), for perioperative bleeding management.
  • Kamrouz Ghadimi, MD, MHSc, Department of Anesthesiology, Duke University, will discuss, "Perioperative Coagulopathic Bleeding – Definition, Treatment Algorithms, and POC Testing, Oh My!"
  • The role of factor concentrates and blood products for management of bleeding in surgery;
    The latest research and current practice guidelines for factor concentrates in perioperative bleeding; and
    Individualized bleeding management strategies in cardiac surgery, with patient case presentations.

Heroes in the Fight: Octapharma To Be Honored for Myositis Research at TMA Annual Patient Conference

Retrieved on: 
Wednesday, September 6, 2023
The New England Journal of Medicine, IBM, Hair, Disease, Polymyositis, Interim, Bell, University, DM, Arthralgia, University of California, Irvine Medical Center, Food and Drug Administration, Skin, Progress, Inflammation, MS, Organization, Heroes, Patient, Swelling, Autoimmune disease, Symbiosis, Grammy Awards, Rare, FDA, ALS, Conference, Food, Pulmonary fibrosis, TMA, Pharmaceutical industry, Myositis, Dermatomyositis, Octapharma, MD, Research

PARAMUS, N.J., Sept. 6, 2023 /PRNewswire/ -- Octapharma USA will be presented with the Research & Development Award for Outstanding Innovation in Myositis Research during the Heroes in the Fight Awards Celebration at The Myositis Association's 2023 International Annual Patient Conference to be held September 7 - 10 in San Diego.

Key Points: 
  • "TMA is grateful to Octapharma for being the first pharmaceutical company to take the chance on a treatment for this rare autoimmune disease of the muscles.
  • "We are honored to be recognized by TMA for Octapharma's groundbreaking research on dermatomyositis," said Octapharma USA President Flemming Nielsen.
  • "TMA and Octapharma are celebrating special anniversaries this year, and we congratulate TMA on 30 great years serving the myositis community.
  • Octapharma is the Premier Sponsor for the conference, which features myositis specialists and expert presenters on everything related to these debilitating diseases.

Octapharma Puts a Spotlight on the Infection Burden in Patients With Chronic Lymphocytic Leukaemia (CLL) at the European Hematology Association (EHA) Hybrid Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
Oncology, Health, Other Science, Research, Pharmaceutical, Science, CLL, Infection, Immunodeficiency, University, Victorian Comprehensive Cancer Centre, University of Padua, COVID-19, Clinical trial, Risk, SID, Congress, Death, Medical director, Patient, Guideline, Rigshospitalet, Immunoglobulin G, Glossary of education terms (G–L), Disease, Hypogammaglobulinemia, Safety, Pharmaceutical industry, Medicine, Octapharma

Secondary immunodeficiency (SID) is a common complication in patients with haematological malignancies such as CLL.

Key Points: 
  • Secondary immunodeficiency (SID) is a common complication in patients with haematological malignancies such as CLL.
  • Finally, Professor Livio Trentin, University of Padua, Italy, will speak about his experience using subcutaneous immunoglobulin therapy for infection prophylaxis in patients with CLL.
  • Stephan Stilgenbauer, Professor of Medicine and Medical Director of the Comprehensive Cancer Centre in Ulm, Germany, will chair the session.
  • The results of this analysis on 3,846 SID patients will be displayed and commented during the poster session of the Congress on June 9, 2023:

European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG® for Pre-Hospital Transfusion

Retrieved on: 
Thursday, February 2, 2023
Chemicals, Plastics, Manufacturing, Stem Cells, Pharmaceutical, Surgery, Medical Devices, Hospitals, Clinical Trials, Other Manufacturing, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, Transfusion medicine, Octapharma, Patient, Shock, Trauma, Temperature, Hypothermia, AB, Survival, Plasma, TIC, Metabolic acidosis, Bleeding, FFP, Death, Pharmaceutical industry, Hospital

Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion.

Key Points: 
  • Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion.
  • The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings.
  • Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death.
  • Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic acidosis, that begins soon after injury.

Octapharma to put the perspectives of patients and clinicians under the spotlight at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Retrieved on: 
Wednesday, January 18, 2023
Haemophilia, Congress, Octapharma, Emicizumab, VIII, Patient, Faculty, Factor VIII, Medical device, Pharmaceutical industry

Treatment decisions need to consider the perspectives of both the patient and the clinician to find the ideal approach for each patient.

Key Points: 
  • Treatment decisions need to consider the perspectives of both the patient and the clinician to find the ideal approach for each patient.
  • The interactive Octapharma symposium at the 16th Annual Congress of EAHAD in Manchester, UK, will present the perspectives of three clinicians and three patients on key treatment decisions encountered during the lives of people with haemophilia A.
  • The three patients and their families will share their experiences, the challenges they have faced, and decisions that they have taken.
  • "We appreciate the importance of bringing together the perspectives of both clinicians and people with haemophilia A in order to provide individualised care and improve the lives of patients."